Fluconazole prophylaxis prevents intra-abdominal candidiasis in high- risk surgical patients

Critical Care Medicine

Volumn 27, Issue 6, 1999, Pages 1066-1072

  Eggimann, Philippe ^a   Francioli, Patrick ^a   Bille, Jacques ^a   Schneider, Rémy ^a   Wu, Mei Miau ^a   Chapuis, Germain ^a   Chiolero, René ^a   Pannatier, André ^a   Schilling, Julian ^b   Geroulanos, Stefanos ^b   Glauser, Michel P ^a   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Division of Hospital Epidemiology Ctr Hosp Universitaire Vaudois ^*

Author keywords

Candida; Candidiasis; Colonization; Critical care; Fluconazole; Infection; Peritoniti s; Prophylaxis; Surgery

Indexed keywords

FLUCONAZOLE;

ABDOMINAL INFECTION; ADULT; AGED; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SURGERY; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0033047638     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199906000-00019     Document Type: Review

References (46)

1. 1. Banerjee SN, Emori TG, Culver DH, et al: Secular trends in nosocomial primary blood-stream infections in the United States, 1980-1989. Am J Med 1991; 91:86S-89S
2. 2. Beck-Sagué CM, Jarvis WR, National Nosocomial Infections Surveillance System: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-1251
3. 3. Wey SB, Mori M, Pfaller MA, et al: Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-2645
4. 4. Pittet D, Li N, Woolson RF, et al: Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068-1078
5. 5. Gaines JD, Remington JS: Disseminated candidiasis in the surgical patient. Surgery 1972; 72:730-736
6. 6. Bayer AS, Blumenkrantz MJ, Montgomerie JZ, et al: Candida peritonitis: Report of 22 cases and review of the English literature. Am J Med 1976; 61:832-840
7. 7. Solomkin JS, Flohr AB, Quie PG, et al: The role of Candida in intraperitoneal infections. Surgery 1980; 88:524-530
8. 8. Calandra T, Bille J, Schneider R, et al: Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; ii:1437-1440
9. 9. Rantala A: Post-operative candidiasis. Ann Chir Gynaecol 1993; 205:2-52
10. 10. Kujath P, Lerch K, Kochendörfer P, et al: Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993; 6:376-382
11. 11. Nathens AB, Rostein OD, Marschall JC: Tertiary peritonitis: Clinical features of a complex nosocomial infection. World J Surg 1998; 22:158-163
12. 12. Marsh PK, Tally FP, Kellum J, et al: Candida infections in surgical patients. Ann Surg 1983; 198:41-47
13. 13. Rutledge R, Mandel SR, Wild RE: Candida species: Insignificant contaminant or pathogenic species. Am Surg 1986; 52:299-302
14. 14. Baron EJ, Weissfeld AS, Fuselier PA, et al: Classification and identification of bacteria. In: Manual of Clinical Microbiology. Sixth Edition. Murray PR, Baron EJ, Pfaller MA, et al (Eds). Washington, DC, American Society for Microbiology Press, 1995, pp 249-264
15. 15. Woods GL, Washington JA: Antibacterial susceptibility tests: Dilution and disk diffusion methods. In: Manual of Clinical Microbiology. Sixth Edition. Murray PR, Baron EJ, Pfaller MA, et al (Eds). Washington, DC, American Society for Microbiology Press, 1995, pp 1327-1341
16. 16. Troillet N, Durussel C, Bille J, et al: Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993; 12:911-915
17. 17. Espinel-Ingroff A, Pfaller MA: Antifungal agents and susceptibility testing. In: Manual of Clinical Microbiology. Sixth Edition. Murray PR, Baron EJ, Pfaller MA, et al (Eds). Washington, DC, American Society for Microbiology Press, 1995, pp 1405-1414
18. 18. Rex JH, Pfaller MA, Galgiani JN, et al: Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24:235-247
19. 19. British Society for Antimicrobial Chemotherapy Working Party: Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20:522-528
20. 20. Edwards JE Jr, Bodey GP, Bowden RA, et al: International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997; 25:43-59
21. 21. Slotman GJ, Burchard KW: Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122:147-151
22. 22. Savino JA, Agarwal N, Wry P, et al: Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36:20-26
23. 23. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infection in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851
24. 24. Winston DJ, Chandrasekar PH, Lazarus HM, et al: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503
25. 25. Menichetti F, Del Favero A, Martino P, et al: Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120:913-918
26. 26. Powderly WG, Finkelstein DM, Feinberg J, et al: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:700-705
27. 27. Wingard JR, Merz WG, Rinaldi MG, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277
28. 28. Gutiérrez F, Wall P, Cohen J: An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK University Hospital. J Hosp Infect 1995; 31:149-152
29. 29. Price MF, LaRocco MT, Gentry LO: Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994; 38:1422-1424
30. 30. van't Wout JW: Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis 1996; 15:238-242
31. 31. Abi-Said D, Anaissie E, Uzun O, et al: The epidemiology of hematogenous candidiasis by different Candida species. Clin Infect Dis 1997; 24:1122-1128
32. 32. Nguyen MH, Peacock JE, Morris AJ, et al: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-623
33. 33. Slavin MA, Osborne B, Adams R, et al: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552
34. 34. Stamos JK, Rowley AH: Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571-575
35. 35. Nolla-Salas J, Sitges-Serra A, Léon-Gil C, et al: Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23:23-30
36. 36. Kunova A, Trupl J, Dluholucky S, et al: Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clin Infect Dis 1995; 21:226-227
37. 37. Iwen PC, Kelly DM, Reed EC, et al: Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995; 20:342-347
38. 38. Goff DA, Koletar SL, Buesching WL, et al: Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995; 20:77-83
39. 39. White MH: Contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 1997; 24:1129-1130
40. 40. Vuffray A, Durussel C, Boerlin P, et al: Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994; 8:708-709
41. 41. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8
42. 42. Denning DW, Baily GG, Hood SV: Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 1997; 16:261-280
43. 43. Martins MD, Rex JH: Resistance to antifungal agents in the critical care setting: Problems and perspectives. New Horiz 1996; 4:338-344
44. 44. Ghannoum MA, Rex JH, Galgiani JN: Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34:489-495
45. 45. Goa KL, Barradell LB: Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50:658-690
46. 46. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263-272